 LA JOLLA, Calif., Aug. 9, 2021 PRNewswire -- Avidity Biosciences, Inc. Nasdaq: RNA, a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates AOCsTM, today reported financial results for the second quarter and six months ended June 30, 2021 and highlighted recent corporate progress. 